Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT in Children with Autism Spectrum Disorder
NCT04948814Phase 1Unknown
- Sponsor
- Tongji Hospital
- Start
- Jun 2022
- Primary completion
- Jun 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label trial of allogeneic fecal microbiota in Autism Spectrum Disorder (ASD), sponsored by Tongji Hospital. Primary endpoint: Autism Diagnostic Observation Scale. Status: unknown.
02
Drugs
allogeneic fecal microbiota
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT04948814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04948814.